Neothetics decimated by submental fat failure test

The biotech had pulled off a $65M IPO on 2014, but its future now looks far from certain.

It was a short and bitter update out of San Diego’s Neothetics today after it said a phase 2 proof-of-concept study for its fat reduction therapy flopped.

Cue its shares nose-diving this morning by more than 70% premarket and was reported along with a failure from another small cap biotech, Matinas, which saw its shares tank 45%—all bringing a jolt to biotech investors who had been riding high on last week’s bump.

RELATED: Biotech bounces as the bones of Trump's plans on pricing emerge

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The midstage proof-of-concept test of Neothetics’ LIPO-202 was looking to reduce submental subcutaneous fat, but “did not demonstrate improvement on any efficacy measurements or separation from placebo.”

Dan Piacquadio, head of Neothetics’ Development Committee, did not mince his words: “We are disappointed in these results, which are unambiguous.”

This could prove serious for the biotech, with Kim Kamdar, Ph.D., a member of Neothetics’ board, saying in a statement: “We are determining the path forward for the company. Our primary objective is to maximize value for our shareholders, and we will be expeditious and diligent in deciding next steps. We will share our future plans shortly.”

RELATED: Biotech Neothetics pulls off a $65M IPO and promptly takes a tumble

That has the whiff of cuts, and maybe more.

Neothetics had $9.7 million in cash as of the end of the first fiscal quarter in 2017. It was down as much as 71% premarket, worth around 75 cents a share.

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.